Navigation Links
EpiCept Accelerates Development of Phase I Clinical Study for Cancer

EpiCept Corporation today announced that with the initiation of a new study center, Tower Cancer Research Foundation in Los Angeles, it will accelerate the recruitment of patients in the currently ongoing Phase I clinical study of EPC2407, a novel small molecule vascular disruption agent (VDA) and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas. The first two cohorts of patients have been completed according to schedule at Scottsdale Healthcare Center. The third cohort is currently ongoing at Scottsdale Healthcare Center and at the University of California, Moores Cancer Center, San Diego.

EPC2407 belongs to a novel class of microtubulin inhibitors discovered by EpiCept. These compounds cause caspase activation, cell cycle arrest, and apoptotic death in cancer cells.

The Phase I trial of EPC2407 is now being conducted in three U.S. cancer centers and will administer increasing doses to small groups in approximately 30-40 patients with advanced stages of solid tumors. The primary objectives of the study are to determine the safety (maximum tolerated dose) and the pharmacokinetic profile of the drug. The study will also characterize the pharmacodynamic effects on tumor blood flow and identify early signs of objective anti-tumor response as measured by CT scans, MRI or PET, in these advanced cancer patients with well vascularized solid tumors.

Dr. Peter J. Rosen, Medical Director at Tower Cancer Research Foundation, stated, "Tower Oncology is very excited to work with EpiCept on the clinical development of EPC2407, a product with a new mechanistic approach, which could offer significant advantages in the fight against cancer."

EpiCept President and Chief Executive Officer Jack Talley commented, "We are pleased to be joined by Tower Cancer Research Foundation in the development of EPC2407 and we believe that their participation will result in our completing the trial ahead of p lan. We expect to be in a position to report the results of this important clinical trial later this year."

EPC2407 has shown promising vascular targeting activity with nanomolar potencies of anti-tumor activity in pre-clinical in vitro and in vivo studies. The molecule has been shown to induce tumor cell apoptosis and selectively inhibit growth of proliferating cell lines, including multi-drug resistant cell lines. Murine models of human tumor xenografts demonstrated EPC2407 inhibits growth of established tumors of a number of different cancer types more effectively than the other VDAs tested and was synergistic when used in combination with anticancer agents, such as Cisplatin. The combination of EPC2407 with other anticancer agents in a Phase 1b trial is planned to follow the current monotherapy trial. EPC2407 is one of two VDA compounds currently in clinical trials discovered through EpiCept's Anti-cancer Screening Apoptosis Program (ASAP). The second compound, Azixa(TM), is part of the EP90745 series of apoptosis inducers, which was licensed by EpiCept to Myriad Genetics, Inc. as part of an exclusive, worldwide development and commercialization agreement. Myriad recently announced that Azixa(TM) has a second mode of action due to vascular disruption activity (VDA). The compound is currently being evaluated in two Phase II human clinical trials, one in patients with primary brain cancer and the other in brain metastases due to melanoma. EpiCept's licensing agreement with Myriad for Azixa includes milestone payments, and sublicensing income as well as future royalties in the event Myriad's development of Azixa continues to progress successfully.
'"/>




Related medicine news :

1. Developmental, neurologic problems common in extremely preterm infants
2. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
3. Missing Protein In Cancer Development
4. Tomatoes Might Inhibit the Development Of Prostate Cancer
5. Pollution Found To Impair Lung Development
6. Treating Depression In Children Could Lead To Poor Bone Development
7. Developmental Origins of Polycystic Ovarian Syndrome
8. Sleep Not Critical For Early Brain Development Of Baby Dolphins
9. ‘Loud Noise’ Research may help in Development of Prosthetics for Eldery
10. Stop Watching TV: Toddler Development Affected
11. Vitamin Supplements During Pregnancy to Boost Fetal Development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/15/2017)... ... January 15, 2017 , ... In this role, Courtney ... United States for the asthma & allergy friendly mark. This certification program was created ... and identify consumer products to be more suitable for the 60+ million people living ...
(Date:1/15/2017)... ... January 15, 2017 , ... "On Tour is a music themed ... and ease," said Christina Austin - CEO of Pixel Film Studios. , On ... edit the style and animation of their slideshows. Place each slide on top of ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... NJ is pleased to announce that it will be assisting HackensackUMC Mountainside with ... and Glen Ridge townships, servicing all surrounding towns. The firm will be working ...
(Date:1/14/2017)... ... 2017 , ... "TransFreeze Volume 3 is a self animating masking transition which allows users to ... X," said Christina Austin - CEO of Pixel Film Studios. , TransFreeze Volume 3 ... one clip to the next. , To use “Cut-Out First” presets, choose a ...
(Date:1/13/2017)... ... 13, 2017 , ... KOAMTAC ®, Inc., a leading manufacturer of Bluetooth ... companion scanner and data collector at the National Retail Federation’s Big Show (NRF17) held ... answer to the market’s need for more compact and rugged devices for collecting barcode ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... 16, 2017  According to Kalorama Information, the ... valued at $4.9 billion for 2016.  The growing ... an aging population with significant diagnostic needs, along ... propelling the market for the modality.  The healthcare ... , focuses on the worldwide market, providing market ...
(Date:1/16/2017)... , January 16, 2017 ... Derivatives Market by Product Type (Methyl, Ethyl, Hydroxyethyl, ... Foods & Beverages, Surface Coatings & Paints), ... by MarketsandMarkets, the market was valued at ... projected to reach USD 6.41 Billion by ...
(Date:1/16/2017)... CRUZ, Calif. , Jan. 16, 2017  Dovetail ... Dovetail™ Hi-C sequencing and assembly service, which yields chromosome-scale ... be presented in a Dovetail-hosted workshop on Jan. 17 ... in San Diego . ... services with the launch of our Dovetail Hi-C offering," ...
Breaking Medicine Technology: